Technology behind Covid tests to be developed to spot diabetes and Lyme disease

Aberdeen-based Vertebrate Antibodies Ltd is working with US biotech firm Innova Medical Group.
Experts who created the technology behind Covid tests are now turning their attention to conditions like diabetes and Lyme disease (Danny Lawson/PA)
PA Archive
Lauren Gilmour12 April 2023

Experts who created the technology behind Covid tests at the height of the pandemic have joined forces with a US biotech firm to develop tests for other conditions such as diabetes and Lyme disease.

Formed by a group of research scientists at the University of Aberdeen, Vertebrate Antibodies Ltd (VAL) has secured investment with Innova Medical Group (IMG) to form a new holding company, EpitogenX.

EpitogenX aims to develop lab-based diagnostic tests for Lyme disease and diabetes, which are notoriously difficult to diagnose early enough to enable timely intervention.

The new tests will be cheaper and more accurate than those currently available.

VAL used its technologies to develop Covid tests as part of the Scottish Government chief scientist office’s rapid response to Covid-19 programme.

I'm confident that this partnership will accomplish great things, and that our technology and products will make a global impact

Dr Abdo Alnabulsi, Vertebrate Antibodies Ltd

Technology called EpitoPredikt was designed to identify specific elements or “hotspots” of the Covid virus that would trigger the body’s immune response.

This will now be used to do the same for other diseases.

Further technology developed during the pandemic called EpitoGen combines and displays molecular elements as they would appear naturally in the pathogen or virus.

This approach enhances the test’s performance, improves sensitivity and can incorporate new strains and variants into the tests.

Dr Abdo Alnabulsi, co-founder of VAL, said: “From the start, we set out to revolutionise the research and clinical sectors with innovative technologies.

“We’re thrilled to have found a partner in IMG who shares our vision and values and is equally committed to developing transformative products.

“I’m confident that this partnership will accomplish great things, and that our technology and products will make a global impact.”

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in